MUC1-based recombinant Bacillus Calmette–Guerin vaccines as candidates for breast cancer immunotherapy

Author： Yuan Shifang   Shi Changhong   Liu Li   Han Wei  

Publisher： Informa Healthcare

ISSN： 1471-2598

Source： Expert Opinion on Biological Therapy, Vol.10, Iss.7, 2010-07, pp. : 1037-1048

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Peptide-based vaccines for cancer immunotherapy

By Brinkman Joeli A   Fausch Steven C   Weber Jeffrey S   Kast W Martin  

Expert Opinion on Biological Therapy, Vol. 4, Iss. 2, 2004-02 ,pp. : 181-198

Informa Healthcare

Access to resources Recommend Favorite

Clinical applications of recombinant virus-based cancer immunotherapy

By Adamina Michel   Daetwiler Silvia   Rosenthal Rachel   Zajac Paul  

Expert Opinion on Biological Therapy, Vol. 5, Iss. 9, 2005-09 ,pp. : 1211-1224

Informa Healthcare

Access to resources Recommend Favorite

MUC1 immunotherapy is here to stay

By Kimura Takashi   Finn Olivera J.  

Expert Opinion on Biological Therapy, Vol. 13, Iss. 1, 2013-01 ,pp. : 35-49

Informa Healthcare

Access to resources Recommend Favorite

Immunotherapy of breast cancer

By Wright Stephen E  

Expert Opinion on Biological Therapy, Vol. 12, Iss. 4, 2012-04 ,pp. : 479-490

Informa Healthcare

Access to resources Recommend Favorite

The O -linked glycosylation of secretoryshed MUC1 from an advanced breast cancer patient's serum

By Storr Sarah J   Royle Louise   Chapman Caroline J   Hamid Umi M Abd   Robertson John F   Murray Andrea   Dwek Raymond A   Rudd Pauline M  

Glycobiology, Vol. 18, Iss. 6, 2008-06 ,pp. : 456-462

Oxford University Press

Access to resources Recommend Favorite